Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Roche perseveres with FAP
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
